Clinical Trials Facility
Retina Consultants of Charleston has over 2000 square feet of space dedicated to research and clinical trials. Our cutting edge technology allows us to be part of the most advanced retina trials worldwide. Our equipment consists of Cirrus, Stratus, and Heidelberg OCT's, digital high definition fundus and fluorescein angiography (FA) cameras, fundus autofluorescence (FAF) Heidelberg cameras (Spectralis HRA+OCT), and a Humphrey visual field. All locations boast dedicated, multi-study certified 4-meter exam lanes with various visual acuity and lighting capabilities to meet protocol-specific requirements, including ETDRS and low luminance. Equipped with separate waiting areas and exam rooms used exclusively for clinical trials, each site also has dedicated, locked storage for clinical trials documents as well as locked, monitored, temperature-controlled refrigerators and freezers.
Clinical Trials Staff
Retina Consultants of Charleston has multiple staff members dedicated to clinical trials that are highly qualified and certified to perform all clinical trial tasks. We have multi-study certified visual acuity technicians and photographers that are certified by the top image reading centers including the DARC, Duke, Wisconsin, and Vienna Reading Centers. At our CLIA certified facilities, we are able to collect and centrifuge all biologic samples on-site. All specimens are packed and shipped by staff that are trained and certified in hazardous material transportation.
Our principal investigators and sub-investigators are board certified ophthalmologists, highly motivated for research, and have extensive backgrounds in clinical trials.
Our program directors include a retina specialist trained in Europe, with extensive experience in clinical trials management and an optometrist trained at the University of Missouri, an ophthalmologist trained in Mexico and a Pharmacist trained in Charleston. Our directors are compassionate, highly meticulous individuals and are always available for patients and clinical trials monitors.
Clinical Trials Patients
Charleston is the oldest city in the state of South Carolina and is currently the second largest city in the state. It was made the county seat of Charleston County in 1901 when Charleston County was created. The population was estimated to be 125,000 in 2009, making it the second most populous city in South Carolina. Current trends put Charleston as the fastest-growing municipality in South Carolina.
Retina Consultants of Charleston has 8 locations that allow us to serve all of Charleston County, Orangeburg County, Florence County, Beaufort County and Colleton County. Our doctors examine patients from all over South Carolina and our referrals come from all over the Southeast. We see more than 2000 patients every month, allowing access to our clinical trial facility to more patients than most of the retina specialists in our area.
I feel quite fortunate to be a patient at Retina Consultants. I participated in a clinical trial for a drug to treat macular degeneration and all of the doctors and staff I encountered through this year long study were so kind, compassionate and professional. My thanks to all of the staff at Retina Consultants.— Debra
Ongoing Clinical Trials
Dry AMD
A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Sponsor: Ionis Pharmaceuticals, Inc.
Status: Recruiting
Locations available: Ladson
Proliferative Diabetic Retinopathy
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
Sponsor: Novartis Pharmaceuticals
Status: Recruiting
Locations available: Ladson
Wet AMD
Effectiveness and Safety of ABP 938 in Patients With Neovascular Age-related Macular Degeneration [Neovascular(Wet)AMD]
Sponsor: Amgen
Status: Recruiting
Locations available: LadsonA Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. (DAZZLE)
Sponsor: Kodiak Sciences Inc
Status: Active, Not Recruiting
Locations available: LadsonSafety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration (CANDELA)
Sponsor: Regeneron Pharmaceuticals
Status: Recruiting
Locations available: LadsonStudy to Gather Information on Safety and Use of High Dose Aflibercept Injection Into the Eye in Patients With an Age Related Eye Disorder That Causes Blurred Vision or a Blind Spot Due to Abnormal Blood Vessels That Leak Fluid Into the Light Sensitive Lining Inside the Eye (PULSAR)
Sponsor: Bayer
Status: Recruiting
Locations available: LadsonA Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
Sponsor: Hoffmann-La Roche
Status: Active, Not Recruiting
Locations available: LadsonEfficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration (PANDA-2)
Sponsor: Chengdu Kanghong Biotech Co., Ltd.
Status: Active, Not Recruiting
Locations: LadsonComparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis®️ in Patients With nAMD (XPLORE)
Sponsor: Xbrane Biopharma AB
Status: Recruiting
Locations: Ladson
Diabetic Macular Edema
A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (RHINE)
Sponsor: Genentech
Status: Enrolling by invitation
Locations available: LadsonA Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema (Rhone-X)
Sponsor: Genentech
Status: Recruiting
Locations available: LadsonThis Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Participants With Diabetic Macular Edema Compared With Intravitreal Ranibizumab (Pagoda)
Sponsor: Genentech
Status: Recruitingon
Locations: LadsonComparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea®️ in Subjects With Diabetic Macular Edema
Sponsor: Mylan Inc.
Status: Active, Not Recruiting
Locations available: LadsonA Trial to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME) (GLEAM)
Sponsor: Kodiak Sciences Inc
Status: Recruiting
Locations available: Beaufort and Ladson
Diabetic Retinopathy
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)
Sponsor: Genentech
Status: Recruiting
Locations available: LadsonA Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy (CANBERRA)
Sponsor: Genentech
Status: Recruiting
Locations available: Ladson
Retinal Vein Occlusion (RVO)
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion (BALATON)
Sponsor: Hoffmann-La Roche
Status: Recruiting
Locations available: LadsonA Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion (COMINO)
Sponsor: Hoffmann-La Roche
Status: Not yet recruiting
Locations available: LadsonA Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) (BEACON)
Sponsor: Kodiak Sciences Inc
Status: Recruiting
Locations available: Beaufort and Ladson
Dry AMD Study
ISEE2008 (GATHER2): A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Sponsor: IVERIC bio, Inc.
Status: Recruiting
Locations available: Beaufort and Ladson
We currently have ongoing studies at all locations for diabetes, macular degeneration, vein occlusion and more. If you are interested in learning more or participating in a clinical trial for macular or retinal disease, please call us at 843-763-4466 or email us at clinicaltrialscni@gmail.com or c.ortiz@retinacharleston.com for our Ladson location, clinicaltrialsRRB@gmail.com or jsmarker@retinacharleston.com for our Beaufort location, p.amezquita@retinacharleston.com for our West Ashley location. You will receive a reply from us within 48 - 72 hours.